EP Patent

EP2784075A1 — Hepatitis C virus inhibitors

Assigned to Bristol Myers Squibb Holdings Ireland ULC · Expires 2014-10-01 · 12y expired

What this patent protects

The present disclosure relates to compounds having the Formula (I), compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of …

USPTO Abstract

The present disclosure relates to compounds having the Formula (I), compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Drugs covered by this patent

Patent Metadata

Patent number
EP2784075A1
Jurisdiction
EP
Classification
—
Expires
2014-10-01
Drug substance claim
No
Drug product claim
No
Assignee
Bristol Myers Squibb Holdings Ireland ULC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.